Anti-lilrb1 nanobody or antigen-binding fragment thereof, preparation method therefor and use thereof
By developing anti-LILRB1 antibodies or antigen-binding fragments, the binding of LILRB1 and HLA-G was blocked, and the problem of inhibition of immune cell function in the prior art was solved, effective killing of tumor cells was achieved, and efficient anti-cancer effects were demonstrated. .
Patent Information
- Application Number
- PCT/CN2023/122586
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-16
- Filing Date
- 2023-09-28
- Publication Date
- 2024-11-21
AI Technical Summary
The prior art is difficult to effectively block the interaction between LILRB1 and HLA-G, leading to inhibition of immune cell function and promoting tumor immune escape.
Develop anti-LILRB1 antibodies or antigen-binding fragments of their antigens to restore immune cell activity by inhibiting the binding of LILRB1 to HLA-G, and use the VHH chain and the antibody constant region sequence to specifically bind LILRB1 to block its interaction with MHC class I molecules.
Effectively inhibit the immune escape mechanism of tumor cells, enhance the killing activity of NK92 cells, primary NK cells and macrophages on tumor cells, and show good biological activity and specificity.
Smart Images

Figure PCTCN2023122586-FTAPPB-I100001 
Figure PCTCN2023122586-FTAPPB-I100002 
Figure PCTCN2023122586-FTAPPB-I100003
Abstract
Description
Anti-LILRB1 nanoantibody or antigen-binding fragment thereof, preparation method and use Technical Field
[0001] The present application relates to the field of immunotechnology, and specifically to anti-LILRB1 antibodies or antigen-binding fragments thereof, preparation methods and applications, especially anti-LILRB1 nanobodies or antigen-binding fragments thereof, preparation methods and applications. Background Art
[0002] Leukocyte immunoglobulin-like receptor subfamily B1 (LILRB1; also known as ILT2, CD85j, or LIR-1) is an inhibitory receptor expressed in cells such as B cells, T cells, NK cells, dendritic cells, macrophages, and other immune cells. LILRB1 is a type I transmembrane glycoprotein with an extracellular Ig-like domain that binds to ligands and an intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM). It can recruit downstream phosphatases such as SHP1, SHP2, and SHIP, and inhibit immune cell activation through a series of signaling pathways.
[0003] LILRB1 is a receptor for MHC class I antigens and recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, and HLA-G, with a particular preference for binding to HLA-G. Furthermore, many cancer cells overexpress HLA-G to facilitate immune evasion. Currently, the interaction between LILRB1 and HLA-G has been shown to inhibit immune cell function, thereby promoting tumor immune evasion. Blocking the binding of LILRB1 to HLA-G is expected to restore suppressed immune cell activity, thereby exerting anti-tumor effects.
[0004] Therefore, there is a need to develop agents that bind to LILRB1 and block the interaction between LILRB1 and HLA-G.
[0005] Summary of the Invention
[0006] In response to the above-mentioned problems existing in the prior art, the present application provides an anti-LILRB1 antibody or an antigen-binding fragment thereof, a preparation method and use thereof. The anti-LILRB1 antibody or antigen-binding fragment thereof can inhibit the immune escape mechanism of tumor cells so that immune cells can exhibit their anti-cancer effects.
[0007] The first aspect of the present application provides an anti-LILRB1 antibody or an antigen-binding fragment thereof, which comprises a VHH chain, wherein the VHH chain comprises complementary determining regions CDR1, CDR2, and CDR3 with the amino acid sequences shown below:
[0008] The CDR1 amino acid sequence is one of the sequences set forth in SEQ ID NO: 1, 4, 7, 10, 13, 16, 19, 22, 29, 32, 33, 34, 36, 39, 43, 46, 49, 51, 54, 56, 58, 61, 64, 67, or 70;
[0009] The CDR2 amino acid sequence is one of SEQ ID NOs: 2, 5, 8, 11, 14, 17, 20, 23, 24, 26, 27, 30, 37, 40, 44, 47, 52, 55, 57, 59, 62, 65, or 68;
[0010] The CDR3 amino acid sequence is one of the sequences shown in SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 25, 28, 31, 35, 38, 41, 42, 45, 48, 50, 53, 60, 63, 66, 69.
[0011] In some embodiments of the present application, the VHH chain comprises:
[0012] (1) CDR1 shown in SEQ ID NO: 1, CDR2 shown in SEQ ID NO: 2, and CDR3 shown in SEQ ID NO: 3; or
[0013] (2) CDR1 shown in SEQ ID NO: 4, CDR2 shown in SEQ ID NO: 5, and CDR3 shown in SEQ ID NO: 6; or
[0014] (3) CDR1 shown in SEQ ID NO: 7, CDR2 shown in SEQ ID NO: 8, and CDR3 shown in SEQ ID NO: 9; or
[0015] (4) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 12; or
[0016] (5) CDR1 shown in SEQ ID NO: 13, CDR2 shown in SEQ ID NO: 14, and CDR3 shown in SEQ ID NO: 15; or
[0017] (6) CDR1 shown in SEQ ID NO: 16, CDR2 shown in SEQ ID NO: 17, and CDR3 shown in SEQ ID NO: 15; or
[0018] (7) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 18; or
[0019] (8) CDR1 shown in SEQ ID NO: 19, CDR2 shown in SEQ ID NO: 20, and CDR3 shown in SEQ ID NO: 21; or
[0020] (9) CDR1 shown in SEQ ID NO: 22, CDR2 shown in SEQ ID NO: 23, and CDR3 shown in SEQ ID NO: 3; or
[0021] (10) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 24, and CDR3 shown in SEQ ID NO: 25;
[0022] (11) CDR1 shown in SEQ ID NO: 13, CDR2 shown in SEQ ID NO: 26, and CDR3 shown in SEQ ID NO: 25; or
[0023] (12) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 25; or
[0024] (13) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 27, and CDR3 shown in SEQ ID NO: 28; or
[0025] (14) CDR1 shown in SEQ ID NO: 29, CDR2 shown in SEQ ID NO: 30, and CDR3 shown in SEQ ID NO: 31; or
[0026] (15) CDR1 shown in SEQ ID NO: 32, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 18; or
[0027] (16) CDR1 shown in SEQ ID NO: 33, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 18; or
[0028] (17) CDR1 shown in SEQ ID NO: 34, CDR2 shown in SEQ ID NO: 23, and CDR3 shown in SEQ ID NO: 35; or
[0029] (18) CDR1 shown in SEQ ID NO: 36, CDR2 shown in SEQ ID NO: 37, and CDR3 shown in SEQ ID NO: 38; or
[0030] (19) CDR1 shown in SEQ ID NO: 39, CDR2 shown in SEQ ID NO: 40, and CDR3 shown in SEQ ID NO: 41; or
[0031] (20) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 42; or
[0032] (21) CDR1 shown in SEQ ID NO:43, CDR2 shown in SEQ ID NO:44, and CDR3 shown in SEQ ID NO:45; or
[0033] (22) CDR1 shown in SEQ ID NO: 46, CDR2 shown in SEQ ID NO: 47, and CDR3 shown in SEQ ID NO: 48; or
[0034] (23) CDR1 shown in SEQ ID NO:49, CDR2 shown in SEQ ID NO:47, and CDR3 shown in SEQ ID NO:50; or
[0035] (24) CDR1 shown in SEQ ID NO: 51, CDR2 shown in SEQ ID NO: 52, and CDR3 shown in SEQ ID NO: 53; or
[0036] (25) CDR1 shown in SEQ ID NO: 54, CDR2 shown in SEQ ID NO: 55, and CDR3 shown in SEQ ID NO: 53; or
[0037] (26) CDR1 shown in SEQ ID NO: 56, CDR2 shown in SEQ ID NO: 57, and CDR3 shown in SEQ ID NO: 53; or
[0038] (27) CDR1 shown in SEQ ID NO: 58, CDR2 shown in SEQ ID NO: 59, and CDR3 shown in SEQ ID NO: 60; or
[0039] (28) CDR1 shown in SEQ ID NO: 61, CDR2 shown in SEQ ID NO: 62, and CDR3 shown in SEQ ID NO: 63; or
[0040] (29) CDR1 shown in SEQ ID NO: 64, CDR2 shown in SEQ ID NO: 65, and CDR3 shown in SEQ ID NO: 66; or
[0041] (30) CDR1 shown in SEQ ID NO: 67, CDR2 shown in SEQ ID NO: 68, and CDR3 shown in SEQ ID NO: 69; or
[0042] (31) CDR1 shown in SEQ ID NO:70, CDR2 shown in SEQ ID NO:59, and CDR3 shown in SEQ ID NO:60.
[0043] In a preferred embodiment, the VHH chain comprises:
[0044] (1) CDR1 shown in SEQ ID NO: 1, CDR2 shown in SEQ ID NO: 2, and CDR3 shown in SEQ ID NO: 3;
[0045] (2) CDR1 shown in SEQ ID NO: 4, CDR2 shown in SEQ ID NO: 5, and CDR3 shown in SEQ ID NO: 6;
[0046] (3) CDR1 shown in SEQ ID NO: 7, CDR2 shown in SEQ ID NO: 8, and CDR3 shown in SEQ ID NO: 9;
[0047] (4) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 12;
[0048] (5) CDR1 shown in SEQ ID NO:43, CDR2 shown in SEQ ID NO:44, and CDR3 shown in SEQ ID NO:45;
[0049] (6) CDR1 shown in SEQ ID NO:46, CDR2 shown in SEQ ID NO:47, and CDR3 shown in SEQ ID NO:48;
[0050] (7) CDR1 shown in SEQ ID NO:51, CDR2 shown in SEQ ID NO:52, and CDR3 shown in SEQ ID NO:53;
[0051] (8) CDR1 shown in SEQ ID NO: 54, CDR2 shown in SEQ ID NO: 55, and CDR3 shown in SEQ ID NO: 53;
[0052] (9) CDR1 shown in SEQ ID NO: 56, CDR2 shown in SEQ ID NO: 57, and CDR3 shown in SEQ ID NO: 53;
[0053] (10) CDR1 shown in SEQ ID NO: 58, CDR2 shown in SEQ ID NO: 59, and CDR3 shown in SEQ ID NO: 60; or
[0054] (11) CDR1 shown in SEQ ID NO:61, CDR2 shown in SEQ ID NO:62, and CDR3 shown in SEQ ID NO:63.
[0055] In a preferred embodiment, the VHH chain comprises:
[0056] (1) CDR1 shown in SEQ ID NO: 1, CDR2 shown in SEQ ID NO: 2, and CDR3 shown in SEQ ID NO: 3;
[0057] (2) CDR1 shown in SEQ ID NO: 4, CDR2 shown in SEQ ID NO: 5, and CDR3 shown in SEQ ID NO: 6;
[0058] (3) CDR1 shown in SEQ ID NO: 7, CDR2 shown in SEQ ID NO: 8, and CDR3 shown in SEQ ID NO: 9;
[0059] (4) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 12;
[0060] (5) CDR1 shown in SEQ ID NO:43, CDR2 shown in SEQ ID NO:44, and CDR3 shown in SEQ ID NO:45;
[0061] (6) CDR1 shown in SEQ ID NO:46, CDR2 shown in SEQ ID NO:47, and CDR3 shown in SEQ ID NO:48;
[0062] (7) CDR1 shown in SEQ ID NO:51, CDR2 shown in SEQ ID NO:52, and CDR3 shown in SEQ ID NO:53;
[0063] (8) CDR1 shown in SEQ ID NO: 54, CDR2 shown in SEQ ID NO: 55, and CDR3 shown in SEQ ID NO: 53; or
[0064] (9) CDR1 shown in SEQ ID NO: 56, CDR2 shown in SEQ ID NO: 57, and CDR3 shown in SEQ ID NO: 53.
[0065] In a further preferred embodiment, the VHH chain comprises:
[0066] (1) CDR1 shown in SEQ ID NO: 1, CDR2 shown in SEQ ID NO: 2, and CDR3 shown in SEQ ID NO: 3; or
[0067] (2) CDR1 shown in SEQ ID NO: 4, CDR2 shown in SEQ ID NO: 5, and CDR3 shown in SEQ ID NO: 6.
[0068] In some embodiments of the present application, the VHH chain has an amino acid sequence as shown in SEQ ID NO: 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 or 82, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence as shown in SEQ ID NO: 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 or 82.
[0069] In some embodiments, the different amino acids between the amino acid sequence shown in SEQ ID NO: 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 or 82 and an amino acid sequence with at least 80% identity thereto are mainly or entirely located in the FR region of the VHH chain.
[0070] In a preferred embodiment, the VHH chain has the amino acid sequence shown in SEQ ID NO: 71, 77, 81 or 82.
[0071] In some embodiments of the present application, the antibody is a nanobody or a heavy chain antibody (HcAb).
[0072] In some embodiments of the present application, the antibody is a nanobody.
[0073] In some embodiments of the present application, the anti-LILRB1 antibody is a heavy chain antibody (HcAb).
[0074] In some embodiments of the present application, the LILRB1 antibody or antigen-binding fragment further comprises an antibody constant region sequence without a CH1 segment; more preferably, the antibody or antigen-binding fragment further comprises an antibody constant region sequence having CH2 and CH3 segments, or the antibody or antigen-binding fragment further comprises an antibody Fc region. Preferably, the antibody constant region or antibody Fc region is connected to the antibody or antigen-binding fragment with or without a connecting peptide. In some embodiments, the antibody or antigen-binding fragment comprises the CH2 and CH3 segments, or the Fc region, of IgG (e.g., IgG1, IgG2, IgG3, or IgG4, preferably IgG4, more preferably human IgG4), preferably the CH2 and CH3 segments or the Fc region of IgG4, the amino acid sequence of which is shown in SEQ ID NO: 87.
[0075] In some embodiments of the present application, the LILRB1 is mammalian LILRB1, and the anti-LILRB1 antibody is preferably a camel-derived nanobody or a humanized nanobody.
[0076] In some specific embodiments of the present application, the anti-LILRB1 antibody is a camel-derived nanobody.
[0077] In some embodiments of the present application, the antibody is an IgG antibody, which can be IgG1, IgG2, IgG3 or IgG4 antibody, preferably IgG4 antibody. In some specific embodiments of the present application, the antibody is an IgG4 antibody.
[0078] In some embodiments of the present application, the antibody is selected from a monoclonal antibody, a polyclonal antibody, a monovalent antibody, a multivalent antibody, a monospecific antibody, and a multispecific antibody.
[0079] In some embodiments of the present application, the antibody is a multivalent antibody comprising at least two VHH chains. Preferably, the multivalent antibody is a bivalent antibody, a trivalent antibody, or a tetravalent antibody. More preferably, the multivalent antibody is a bivalent antibody.
[0080] In some embodiments of the present application, the antibody is a multispecific antibody that specifically binds to LILRB1 and additionally specifically binds to one or more other targets. Preferably, the multispecific antibody, such as a bispecific antibody, further comprises at least one second antibody having a second binding specificity for a second target. Preferably, the multispecific antibody is a bispecific antibody, a trispecific antibody, or a tetraspecific antibody. More preferably, the multispecific antibody is a bispecific antibody.
[0081] In some embodiments of the present application, the antibody or antigen-binding fragment thereof comprises a framework region of a camel-derived heavy chain antibody or a heavy chain framework region derived from a human immunoglobulin.
[0082] The second aspect of the present application provides a nucleic acid molecule encoding the anti-LILRB1 antibody or antigen-binding fragment thereof according to the first aspect.
[0083] The third aspect of the present application provides a recombinant vector comprising the nucleic acid molecule described in the second aspect.
[0084] The fourth aspect of the present application provides a recombinant cell, which comprises the nucleic acid molecule described in the second aspect or the recombinant vector described in the third aspect.
[0085] The fifth aspect of the present application provides a method for preparing an anti-LILRB1 antibody or an antigen-binding fragment thereof, which comprises culturing the recombinant cell described in the fourth aspect.
[0086] In a sixth aspect, the present application provides use of the anti-LILRB1 antibody or antigen-binding fragment thereof described in the first aspect, the nucleic acid molecule described in the second aspect, the recombinant vector described in the third aspect, or the recombinant cell described in the fourth aspect in the preparation of a medicament.
[0087] Preferably, the drug is a drug for preventing and / or treating cancer.
[0088] In some embodiments, the present application relates to the anti-LILRB1 antibody or antigen-binding fragment thereof described in the first aspect of the present application, the nucleic acid molecule described in the second aspect, the recombinant vector described in the third aspect, or the recombinant cell described in the fourth aspect of the present application for preventing and / or treating a LILRB1-related disease. Alternatively, the present application relates to a method for preventing and / or treating a LILRB1-related disease, comprising administering to a subject in need thereof the anti-LILRB1 antibody or antigen-binding fragment thereof described in the first aspect of the present application, the nucleic acid molecule described in the second aspect, the recombinant vector described in the third aspect, or the recombinant cell described in the fourth aspect.
[0089] In a seventh aspect, the present application provides use of the anti-LILRB1 antibody or antigen-binding fragment thereof described in the first aspect in the preparation of a reagent for diagnosing a LILRB1-related disease. In some embodiments, the present application relates to the anti-LILRB1 antibody or antigen-binding fragment thereof described in the first aspect, the nucleic acid molecule described in the second aspect, the recombinant vector described in the third aspect, or the recombinant cell described in the fourth aspect for diagnosing a LILRB1-related disease.
[0090] Preferably, the LILRB1-related disease is cancer. In some embodiments of the present application, the cancer is a cancer expressing MHC class I molecules, preferably a cancer expressing HLA-G.
[0091] In some embodiments, the present application provides a chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signal transduction domain, wherein the extracellular antigen binding domain comprises the anti-LILRB1 antibody or an antigen-binding fragment thereof described herein.
[0092] In some embodiments, the present application provides a kit comprising the anti-LILRB1 antibody or antigen-binding fragment thereof, or chimeric antigen receptor described herein.
[0093] Beneficial effects of this application:
[0094] The anti-LILRB1 antibody or its antigen-binding fragment provided in the present application can inhibit the immune escape mechanism of tumor cells so that immune cells can exhibit their anti-cancer effects, has the activity of promoting NK92 cells, primary NK cells, and macrophages to kill tumor cells, can bind to LILRB1, and block the binding of LILRB1 to HLA-G.
[0095] The anti-LILRB1 antibody or antigen-binding fragment thereof of the present application contains a VHH chain and can be a nanobody or a heavy chain antibody, and has good biological activity. BRIEF DESCRIPTION OF THE DRAWINGS
[0096] FIG1 is a graph showing the reporter gene activity results of the positive control BND-22 of this application;
[0097] Figure 2 is a graph showing the activity detection results of the nanobody reporter gene assay (representative graph);
[0098] 2A is a graph showing the activity detection results of the nanobody BND-22 reporter gene method, FIG. 2B is a graph showing the activity detection results of the nanobody 3-A1 reporter gene method, FIG. 2C is a graph showing the activity detection results of the nanobody 3-C8 reporter gene method, and FIG. 2D is a graph showing the activity detection results of the nanobody 3-D8 reporter gene method;
[0099] Figure 3 is a graph showing the binding detection results of nanobodies and cynomolgus monkey LILRB1 stably transfected cell lines;
[0100] Figure 4 is a graph showing the binding detection results of nanobodies and cynomolgus monkey LILRB1 stably transfected cell lines;
[0101] Figure 5 is a representative graph showing the detection results of the nanobody NK92 cell killing experiment;
[0102] Among them, Figure 5A is a graph showing the detection results of the nanobody BND-22NK92 cell killing experiment, Figure 5B is a graph showing the detection results of the nanobody 3-A1NK92 cell killing experiment, Figure 5C is a graph showing the detection results of the nanobody 3-C8NK92 cell killing experiment, and Figure 5D is a graph showing the detection results of the nanobody 3-D8NK92 cell killing experiment;
[0103] Figure 6 is a graph showing the detection results of the nanobody primary NK cell killing experiment;
[0104] FIG7 is a graph showing the detection results of the nanobody macrophage killing experiment;
[0105] Figure 8 shows the detection results of the humanized nanobody primary NK cell killing experiment. DETAILED DESCRIPTION
[0106] In order to make the present application easier to understand, the present application will be described in detail below with reference to embodiments. These embodiments are merely illustrative and do not limit the scope of application of the present application.
[0107] Unless otherwise defined, the various technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs. See, for example, Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, NY 1994); Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Springs Harbor Press (Cold Springs Harbor, NY 1989); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing Inc., New York, USA (2012); Abbas et al., Cellular and Molecular Immunology, Elsevier Science Health Science div (2009); He Wei et al., Medical Immunology (2nd ed.), People's Medical Publishing House, 2010.
[0108] Unless otherwise indicated, the terms "comprise, comprises and comprising" or their equivalents (contain, contains, containing, include, includes, including) used herein are open-ended expressions, meaning that in addition to the listed elements, components and steps, other unspecified elements, components and steps may also be included. Unless otherwise indicated, the terms "optional" or "optionally" used herein indicate that the object or event it modifies is present or absent, or occurs or does not occur. Unless otherwise indicated, the term "subject" used herein encompasses any vertebrate, such as mammals and non-mammals, such as humans, non-human primates, sheep, dogs, cats, horses, cows, chickens, pigs, mice, etc. Unless otherwise indicated, all numbers used herein to express the amount of ingredients, measurements or reaction conditions should be understood to be modified by the term "about" in all cases. When connected with a percentage, the term "about" can mean, for example, ±1%, preferably ±0.5%, and more preferably ±0.1%. In this article, unless the context clearly dictates otherwise, singular terms encompass plural referents and vice versa. As used herein, the word "or" is intended to include "and" unless the context clearly indicates otherwise.
[0109] Unless otherwise indicated, the term "treat" as used herein means that after administration, the disease or its related symptoms can be inhibited, contained, alleviated, improved, slowed down, relieved or eliminated, the progression of the disease or its related symptoms can be delayed, postponed, slowed down, stopped or terminated, or the recurrence of the disease or its related symptoms can be prevented, controlled or reduced.
[0110] The term "antibody" refers to a polypeptide encoded by an immunoglobulin gene and capable of binding an antigen.
[0111] "Conventional" antibodies are tetrameric (such as the case of G-type immunoglobulins (IgG) in humans), consisting of two identical polypeptide chains called light chains and two identical polypeptide chains called heavy chains. The variable domain is located at the N-terminus of each chain ("VH" for the heavy chain and "VL" for the light chain), and the two variable domains VH and VL are capable of recognizing antigens. Each variable domain typically contains four "framework regions" (called FR1, FR2, FR3, and FR4) and three regions directly responsible for antigen binding, called "CDRs" (called CDR1, CDR2, and CDR3). Typically, each variable domain has the following structure: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. Typically, binding to the antigen is achieved through a pair of variable domains (i.e., the light chain variable domain VL and the heavy chain variable domain VH) (such as the case of human IgG), that is, six CDRs participate in the formation of one antigen binding site.
[0112] The term "heavy-chain antibody" or "HcAb" refers to a functional antibody that contains heavy chains but lacks the light chains typically found in four-chain antibodies. HcAbs are known to be produced by camelids (e.g., camels, llamas, or alpacas). Heavy-chain antibodies lack light chains and the heavy chain constant region 1 (CH1), consisting of only two heavy chains consisting of a variable region (VHH) and another constant region, connected to the constant region by a hinge-like structure. Each heavy chain of a camelid heavy-chain antibody contains one variable region (VHH) and two constant regions (CH2 and CH3).
[0113] The antigen-binding fragment of a heavy chain antibody includes an isolated CDR region, a VHH, and a single-chain heavy chain antibody. By fusion with the constant region of human IgG Fc, a heavy chain antibody can have the CH2 and CH3 of human IgG Fc. "Heavy chain variable region domain of a heavy chain antibody," "VHH," and "nanobody" are used interchangeably.
[0114] Unless otherwise indicated, the scope of the CDRs of the antibodies described in this application has been defined according to the ImMunoGenTics (IMGT) numbering convention, but those skilled in the art will appreciate that CDR sequences numbered according to any one or more of the AbM numbering convention, the Kabat numbering convention, the Chothia numbering convention, and the Contact numbering convention (based on analysis of available complex crystal structures) also fall within the scope of protection of this application.
[0115] In some embodiments of the present application, an anti-LILRB1 antibody or an antigen-binding fragment thereof is provided, which comprises a VHH chain, wherein the VHH chain comprises complementary determining regions CDR1, CDR2, and CDR3 with the amino acid sequences shown below:
[0116] The CDR1 amino acid sequence is one of the sequences set forth in SEQ ID NO: 1, 4, 7, 10, 13, 16, 19, 22, 29, 32, 33, 34, 36, 39, 43, 46, 49, 51, 54, 56, 58, 61, 64, 67, or 70;
[0117] The CDR2 amino acid sequence is one of SEQ ID NOs: 2, 5, 8, 11, 14, 17, 20, 23, 24, 26, 27, 30, 37, 40, 44, 47, 52, 55, 57, 59, 62, 65, or 68;
[0118] The CDR3 amino acid sequence is one of the sequences set forth in SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 25, 28, 31, 35, 38, 41, 42, 45, 48, 50, 53, 60, 63, 66, or 69;
[0119] In some embodiments of the present application, the VHH chain comprises:
[0120] (1) CDR1 shown in SEQ ID NO: 1, CDR2 shown in SEQ ID NO: 2, and CDR3 shown in SEQ ID NO: 3; or
[0121] (2) CDR1 shown in SEQ ID NO: 4, CDR2 shown in SEQ ID NO: 5, and CDR3 shown in SEQ ID NO: 6; or
[0122] (3) CDR1 shown in SEQ ID NO: 7, CDR2 shown in SEQ ID NO: 8, and CDR3 shown in SEQ ID NO: 9; or
[0123] (4) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 12; or
[0124] (5) CDR1 shown in SEQ ID NO: 13, CDR2 shown in SEQ ID NO: 14, and CDR3 shown in SEQ ID NO: 15; or
[0125] (6) CDR1 shown in SEQ ID NO: 16, CDR2 shown in SEQ ID NO: 17, and CDR3 shown in SEQ ID NO: 15; or
[0126] (7) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 18; or
[0127] (8) CDR1 shown in SEQ ID NO: 19, CDR2 shown in SEQ ID NO: 20, and CDR3 shown in SEQ ID NO: 21; or
[0128] (9) CDR1 shown in SEQ ID NO: 22, CDR2 shown in SEQ ID NO: 23, and CDR3 shown in SEQ ID NO: 3; or
[0129] (10) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 24, and CDR3 shown in SEQ ID NO: 25;
[0130] (11) CDR1 shown in SEQ ID NO: 13, CDR2 shown in SEQ ID NO: 26, and CDR3 shown in SEQ ID NO: 25; or
[0131] (12) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 25; or
[0132] (13) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 27, and CDR3 shown in SEQ ID NO: 28; or
[0133] (14) CDR1 shown in SEQ ID NO: 29, CDR2 shown in SEQ ID NO: 30, and CDR3 shown in SEQ ID NO: 31; or
[0134] (15) CDR1 shown in SEQ ID NO: 32, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 18; or
[0135] (16) CDR1 shown in SEQ ID NO: 33, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 18; or
[0136] (17) CDR1 shown in SEQ ID NO: 34, CDR2 shown in SEQ ID NO: 23, and CDR3 shown in SEQ ID NO: 35; or
[0137] (18) CDR1 shown in SEQ ID NO: 36, CDR2 shown in SEQ ID NO: 37, and CDR3 shown in SEQ ID NO: 38; or
[0138] (19) CDR1 shown in SEQ ID NO: 39, CDR2 shown in SEQ ID NO: 40, and CDR3 shown in SEQ ID NO: 41; or
[0139] (20) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 42; or
[0140] (21) CDR1 shown in SEQ ID NO:43, CDR2 shown in SEQ ID NO:44, and CDR3 shown in SEQ ID NO:45; or
[0141] (22) CDR1 shown in SEQ ID NO: 46, CDR2 shown in SEQ ID NO: 47, and CDR3 shown in SEQ ID NO: 48; or
[0142] (23) CDR1 shown in SEQ ID NO:49, CDR2 shown in SEQ ID NO:47, and CDR3 shown in SEQ ID NO:50; or
[0143] (24) CDR1 shown in SEQ ID NO: 51, CDR2 shown in SEQ ID NO: 52, and CDR3 shown in SEQ ID NO: 53; or
[0144] (25) CDR1 shown in SEQ ID NO: 54, CDR2 shown in SEQ ID NO: 55, and CDR3 shown in SEQ ID NO: 53; or
[0145] (26) CDR1 shown in SEQ ID NO: 56, CDR2 shown in SEQ ID NO: 57, and CDR3 shown in SEQ ID NO: 53; or
[0146] (27) CDR1 shown in SEQ ID NO: 58, CDR2 shown in SEQ ID NO: 59, and CDR3 shown in SEQ ID NO: 60; or
[0147] (28) CDR1 shown in SEQ ID NO: 61, CDR2 shown in SEQ ID NO: 62, and CDR3 shown in SEQ ID NO: 63; or
[0148] (29) CDR1 shown in SEQ ID NO: 64, CDR2 shown in SEQ ID NO: 65, and CDR3 shown in SEQ ID NO: 66; or
[0149] (30) CDR1 shown in SEQ ID NO: 67, CDR2 shown in SEQ ID NO: 68, and CDR3 shown in SEQ ID NO: 69; or
[0150] (31) CDR1 shown in SEQ ID NO:70, CDR2 shown in SEQ ID NO:59, and CDR3 shown in SEQ ID NO:60.
[0151] In a preferred embodiment, the VHH chain comprises:
[0152] (1) CDR1 shown in SEQ ID NO: 1, CDR2 shown in SEQ ID NO: 2, and CDR3 shown in SEQ ID NO: 3;
[0153] (2) CDR1 shown in SEQ ID NO: 4, CDR2 shown in SEQ ID NO: 5, and CDR3 shown in SEQ ID NO: 6;
[0154] (3) CDR1 shown in SEQ ID NO: 7, CDR2 shown in SEQ ID NO: 8, and CDR3 shown in SEQ ID NO: 9;
[0155] (4) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 12;
[0156] (5) CDR1 shown in SEQ ID NO:43, CDR2 shown in SEQ ID NO:44, and CDR3 shown in SEQ ID NO:45;
[0157] (6) CDR1 shown in SEQ ID NO:46, CDR2 shown in SEQ ID NO:47, and CDR3 shown in SEQ ID NO:48;
[0158] (7) CDR1 shown in SEQ ID NO:51, CDR2 shown in SEQ ID NO:52, and CDR3 shown in SEQ ID NO:53;
[0159] (8) CDR1 shown in SEQ ID NO: 54, CDR2 shown in SEQ ID NO: 55, and CDR3 shown in SEQ ID NO: 53;
[0160] (9) CDR1 shown in SEQ ID NO: 56, CDR2 shown in SEQ ID NO: 57, and CDR3 shown in SEQ ID NO: 53;
[0161] (10) CDR1 shown in SEQ ID NO: 58, CDR2 shown in SEQ ID NO: 59, and CDR3 shown in SEQ ID NO: 60; or
[0162] (11) CDR1 shown in SEQ ID NO:61, CDR2 shown in SEQ ID NO:62, and CDR3 shown in SEQ ID NO:63.
[0163] In a preferred embodiment, the VHH chain comprises:
[0164] (1) CDR1 shown in SEQ ID NO: 1, CDR2 shown in SEQ ID NO: 2, and CDR3 shown in SEQ ID NO: 3;
[0165] (2) CDR1 shown in SEQ ID NO: 4, CDR2 shown in SEQ ID NO: 5, and CDR3 shown in SEQ ID NO: 6;
[0166] (3) CDR1 shown in SEQ ID NO: 7, CDR2 shown in SEQ ID NO: 8, and CDR3 shown in SEQ ID NO: 9;
[0167] (4) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 12;
[0168] (5) CDR1 shown in SEQ ID NO:43, CDR2 shown in SEQ ID NO:44, and CDR3 shown in SEQ ID NO:45;
[0169] (6) CDR1 shown in SEQ ID NO:46, CDR2 shown in SEQ ID NO:47, and CDR3 shown in SEQ ID NO:48;
[0170] (7) CDR1 shown in SEQ ID NO:51, CDR2 shown in SEQ ID NO:52, and CDR3 shown in SEQ ID NO:53;
[0171] (8) CDR1 shown in SEQ ID NO: 54, CDR2 shown in SEQ ID NO: 55, and CDR3 shown in SEQ ID NO: 53; or
[0172] (9) CDR1 shown in SEQ ID NO: 56, CDR2 shown in SEQ ID NO: 57, and CDR3 shown in SEQ ID NO: 53.
[0173] The present application also provides conservatively modified forms of anti-LILRB1 antibodies or antigen-binding fragments thereof. Those skilled in the art will recognize that a conservative amino acid substitution is a substitution of one amino acid with another amino acid having similar structural or chemical properties (e.g., similar side chains). Exemplary conservative substitutions are described in the art, for example, in Watson et al., Molecular Biology of the Gene, The Bengamin / Cummings Publication Company, 4th edition (1987).
[0174] In a further preferred embodiment, the VHH chain comprises:
[0175] (1) CDR1 shown in SEQ ID NO: 1, CDR2 shown in SEQ ID NO: 2, and CDR3 shown in SEQ ID NO: 3; or
[0176] (2) CDR1 shown in SEQ ID NO: 4, CDR2 shown in SEQ ID NO: 5, and CDR3 shown in SEQ ID NO: 6.
[0177] In some embodiments of the present application, the VHH chain has an amino acid sequence as shown in SEQ ID NO: 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 or 82, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence as shown in SEQ ID NO: 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 or 82. In some embodiments, the different amino acids between the amino acid sequence shown in SEQ ID NO: 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 or 82 and an amino acid sequence with at least 80% identity thereto are all located in the FR region of the VHH chain.
[0178] In a preferred embodiment, the VHH chain has the amino acid sequence shown in SEQ ID NO: 71, 77, 81 or 82.
[0179] In some embodiments of the present application, the antibody is a nanobody or a heavy chain antibody (HcAb).
[0180] In some embodiments of the present application, the antibody is a nanobody.
[0181] In some embodiments of the present application, the anti-LILRB1 antibody is a heavy chain antibody (HcAb).
[0182] In some embodiments of the present application, the LILRB1 antibody or antigen-binding fragment further comprises an antibody constant region sequence without a CH1 segment; more preferably, the antibody or antigen-binding fragment further comprises an antibody constant region sequence with CH2 and CH3 segments, or the antibody or antigen-binding fragment further comprises an antibody Fc region. Preferably, the antibody constant region or antibody Fc region is connected with or without a connecting peptide (e.g., (G4S) n , n is an integer selected from 1-5) is connected to the antibody or antigen-binding fragment. In some embodiments, the antibody or antigen-binding fragment comprises the CH2 and CH3 fragments or Fc region of IgG (e.g., human IgG1, IgG2, IgG3, or IgG4), preferably the CH2 and CH3 fragments or Fc region of IgG4, the amino acid sequence of which is shown in SEQ ID NO: 87.
[0183] In some embodiments of the present application, the LILRB1 is mammalian LILRB1, and the anti-LILRB1 antibody is preferably a camel-derived nanobody or a humanized nanobody.
[0184] In some specific embodiments of the present application, the antibody is a camel-derived nanobody.
[0185] In some embodiments of the present application, the antibody is an IgG antibody, which can be IgG1, IgG2, IgG3 or IgG4 antibody, preferably an IgG4 antibody.
[0186] In some embodiments of the present application, the antibody is selected from a monoclonal antibody, a polyclonal antibody, a monovalent antibody, a multivalent antibody, a monospecific antibody, and a multispecific antibody.
[0187] In some embodiments of the present application, the antibody is a multivalent antibody comprising at least two VHH chains. Preferably, the multivalent antibody is a bivalent antibody, a trivalent antibody, or a tetravalent antibody. More preferably, the multivalent antibody is a bivalent antibody.
[0188] In some embodiments of the present application, the antibody is a multispecific antibody that specifically binds to LILRB1 and additionally specifically binds to one or more other targets. Preferably, the multispecific antibody, such as a bispecific antibody, further comprises at least one second antibody having a second binding specificity for a second target. Preferably, the multispecific antibody is a bispecific antibody, a trispecific antibody, or a tetraspecific antibody. More preferably, the multispecific antibody is a bispecific antibody.
[0189] As non-limiting examples, the anti-LILRB1 antibodies or antigen-binding fragments thereof described herein may exhibit the following properties:
[0190] (1) binds to LILRB1; and / or
[0191] (2) blocking the binding of LILRB1 to MHC class I molecules (preferably HLA-G); and / or
[0192] (3) Enhance the killing effect of immune cells on tumor cells.
[0193] In some embodiments, binding to LILRB1 comprises binding to LILRB1 of a mammal, including humans, non-human primates (e.g., cynomolgus monkeys), and camelids. In some embodiments, binding to LILRB1 comprises binding to cells expressing LILRB1. The anti-LILRB1 antibody or antigen-binding fragment thereof can cross-bind to human and cynomolgus monkey LILRB1, or to cells expressing human or cynomolgus monkey LILRB1.
[0194] In some embodiments, enhancing the killing effect of immune cells on tumor cells includes enhancing the killing effect of NK cells and / or macrophages on tumor cells. In some embodiments, the anti-LILRB1 antibody or antigen-binding fragment thereof blocks the IC537 of HLA-G binding to LILRB1. 50 <2.6μg / mL, <1.1μg / mL, <0.2μg / mL or <0.05μg / mL.
[0195] In some embodiments of the present application, a nucleic acid molecule is provided, which encodes the anti-LILRB1 antibody or antigen-binding fragment thereof.
[0196] In some embodiments of the present application, a recombinant vector is provided, which comprises the nucleic acid molecule.
[0197] The term "vector" refers to a tool for expressing a target gene in a host cell, such as a plasmid vector, a cosmid vector, and a viral vector such as a phage vector, a lentiviral vector, an adenoviral vector, a retroviral vector, and an adeno-associated viral vector. Recombinant vectors can be constructed by or by manipulating plasmids (e.g., pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8 / 9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pHV14, pGEX series, pET series, pUC19, etc.), phages (e.g., λgt4λB, λ-Charon, λΔz1, M13, etc.), or viral vectors (e.g., SV40, etc.), which are commonly used in the art.
[0198] In a recombinant vector, a nucleic acid molecule can be operably linked to a promoter. The term "operably linked" is intended to refer to a functional connection between a target nucleotide sequence and an expression control sequence (e.g., a promoter sequence). When "operably linked," a regulatory element can control the transcription and / or translation of the target polynucleotide.
[0199] Recombinant vectors can generally be constructed as cloning vectors or expression vectors. For recombinant expression vectors, vectors commonly available in the relevant art for expressing foreign proteins in plants, animals, or microbial cells can be used. Various methods well known in the art can be used to construct recombinant vectors.
[0200] In order to use in a host such as a prokaryotic or eukaryotic cell, a recombinant vector can be constructed accordingly. For example, when constructing a vector as an expression vector for a prokaryotic host, the vector generally includes a strong promoter for transcription (e.g., pLλ promoter, CMV promoter, trp promoter, lac promoter, tac promoter, T7 promoter, etc.), a ribosome binding site for initiating translation, and a transcription / translation termination sequence. On the other hand, expression vectors for eukaryotic hosts include replication origins that can be operated in eukaryotic cells, such as f1 replication origin, SV40 replication origin, pMB1 replication origin, adenovirus replication origin, AAV replication origin, and BBV replication origin, but are not limited thereto. In addition, expression vectors generally include promoters derived from mammalian cell genomes (e.g., metallothionein promoters) or promoters derived from mammalian viruses (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus promoter, tk promoter of HSV, etc.), and a polyadenylation sequence as a transcription termination sequence. Recombinant cells can be prepared by introducing the recombinant vector into a suitable host cell. Any host cell known in the art can be used in the present disclosure, as long as it allows the recombinant vector to be continuously cloned and expressed in a stable manner. Examples of prokaryotic host cells that can be used in the present disclosure can be selected from Escherichia coli (E. coli) such as E. coli JM109, E. coli BL21, E. coli RR1, E. coli LE392, E. coli B, E. coli X1776, E. coli W3110, Bacillus species such as Bacillus subtilis and Bacillus thuringiensis, and Enterobacteriaceae strains, such as Salmonella typhimurium, Serratia marcescens and various Pseudomonas species. The eukaryotic host cell that can be used for conversion can be selected from, but is not limited to, yeast saccharomyces cerevisiae (Saccharomyces cerevisiae), insect cell and zooblast, for example Sp2 / 0, CHO (Chinese hamster ovary) K1, CHO DG44, CHO S, CHO DXB11, CHO GS.KO, PER.C6, W138, BHK, COS.7, 293, HepG2, Huh7, 3T3, RIN, MDCK etc.Can use method well-known in the relevant art that nucleic acid molecule or the recombinant vector carrying nucleic acid molecule are introduced (transfection) into host cell.For example, when host cell is prokaryotic cell, can use CaCl Or electroporation method carries out this transfection.For eukaryotic host cell, can use, but is not limited to microinjection, calcium phosphate precipitation, electroporation, liposome-mediated transfection or particle bombardment realize gene introduction.
[0201] In order to select transformed host cells, the phenotype associated with the selection marker can be utilized according to methods well known in the art. For example, when the selection marker is a gene that confers resistance to certain antibiotics, the host cells can be grown in culture medium in the presence of antibiotics to select target transformants.
[0202] In some embodiments of the present application, a recombinant cell is provided, which comprises the nucleic acid molecule or the recombinant vector described herein.
[0203] In some embodiments, the recombinant cell may be a recombinant CHO cell (such as a recombinant CHO-S cell, a recombinant CHO-K1 cell), a recombinant 293 cell, or a recombinant 293T cell.
[0204] In some embodiments of the present application, a method for preparing an anti-LILRB1 antibody or an antigen-binding fragment thereof is provided, comprising culturing the recombinant cell. The method may further comprise isolating and / or purifying the antibody or fragment thereof from the cell culture after the expression or culturing step, for example, by purification using a Protein A affinity column.
[0205] In some embodiments of the present application, provided is a use of the anti-LILRB1 antibody or antigen-binding fragment thereof, the nucleic acid molecule, the recombinant vector or the recombinant cell in preparing a drug.
[0206] In some embodiments of the present application, the drug is a drug for preventing and / or treating cancer.
[0207] In some embodiments of the present application, provided is a use of the anti-LILRB1 antibody or antigen-binding fragment thereof in the preparation of a reagent for diagnosing LILRB1-related diseases.
[0208] Preferably, the LILRB1-related disease is cancer.
[0209] Cancer cells that can be killed according to the present disclosure include, but are not limited to, cancer cells from the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestinal tract, gums, head, kidney, liver, lung, nasopharynx, neck, ovary, prostate, skin, stomach, pancreas, testicles, tongue, cervix, or uterus.
[0210] In addition, the cancer may specifically be of the following histological types, although not limited thereto: tumor, malignant neoplasm; carcinoma; undifferentiated carcinoma; giant cell and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; cortical carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant neoplasm; bile duct carcinoma; hepatocellular carcinoma; mixed hepatocellular and bile duct carcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenoma in adenomatous polyps; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumor, malignant neoplasm; branching alveolar adenocarcinoma; papillary adenocarcinoma; chromophobe cell carcinoma; oncocytic cell carcinoma; oncocytic adenocarcinoma; basophilic cell carcinoma; clear cell adenocarcinoma; granulosa cell carcinoma; follicular adenocarcinoma; papillary and follicular adenocarcinoma; non-encapsulated sclerosing carcinoma; adrenocortical carcinoma; endometrioid carcinoma; carcinoma of skin appendages; apocrine carcinoma; sebaceous carcinoma; cerumenic carcinoma; mucoepidermoid carcinoma; cystadenocarcinoma; papillary cystadenocarcinoma; papillary serous cystadenocarcinoma; mucinous cystadenocarcinoma; mucinous adenocarcinoma; signet ring cell carcinoma; infiltrating ductal carcinoma; medullary carcinoma; lobular carcinoma; inflammatory carcinoma; Paget's disease of the breast; acinar cell carcinoma; adenosquamous carcinoma; adenocarcinoma with squamous metaplasia; thymoma, malignant; ovarian stromal tumor, malignant; thecoma cell tumor, malignant; granulosa cell tumor, malignant; androblastoma, malignant; Sertoli cell carcinoma; Leydig cell tumor, malignant; lipid cell tumor, malignant; paraganglioma, malignant; extramammary paraganglioma, malignant; pheochromocytoma; Glomus sarcoma; malignant melanoma; amelanotic melanoma; surface-expanding melanoma; malignant melanoma in giant nevus; epithelioid cell melanoma; blue nevus, malignant tumor; sarcoma; fibrosarcoma; fibrohistiocytoma, malignant tumor; myxosarcoma; liposarcoma; leiomyosarcoma; rhabdomyosarcoma; embryonal rhabdomyosarcoma; alveolar rhabdomyosarcoma; stromal sarcoma; mixed tumor, malignant tumor; mixed Müllerian tumor; Wilms' tumor; hepatoblastoma; carcinosarcoma; stromal tumor, malignant tumor; Brenner's tumor, malignant tumor; phyllodes tumor, malignant tumor; synovial sarcoma; mesothelioma, malignant tumor; dysgerminoma; embryonal carcinoma; teratoma, malignant tumor; thyroid gland Ovarian tumor, malignant tumor; Choriocarcinoma; Mesonephroma, malignant tumor; Angiosarcoma; Hemangioendothelioma, malignant tumor; Kaposi's sarcoma; Hemangiopericytoma, malignant tumor; Lymphangiosarcoma; Osteosarcoma; Juxtacortical osteosarcoma; Chondrosarcoma; Chondroblastoma, malignant tumor; Interstitial chondrosarcoma; Giant cell tumor of bone; Ewing's sarcoma; Odontogenic tumor, malignant tumor; Ameloblastic odontosarcoma; Ameloblastoma, malignant tumor; Ameloblastic fibrosarcoma; Pineal tumor, malignant tumor; Chordoma; Glioma, malignant tumor; Ependymoma; Astrocytoma; Protoplasmic astrocytoma; Fibrillary astrocytoma; Astroblastoma; Glioblastoma; Oligodendroglioma; Oligodendroglioblastoma; Primitive neuroectodermal tumor;Cerebellar sarcoma; ganglioblastoma; neuroblastoma; retinoblastoma; olfactory neurogenic tumor; meningioma, malignant; neurofibrosarcoma; neurilemoma, malignant; granular cell tumor, malignant; malignant lymphoma; Hodgkin's disease; paragranuloma; malignant lymphoma, small lymphocytic; malignant lymphoma, large cell, diffuse; malignant lymphoma, follicular; mycosis fungoides; other specified non-Hodgkin's lymphoma; malignant histiocytosis; multiple myeloma; mast cell sarcoma; immunoproliferative small intestinal disease; leukemia; lymphoid leukemia; plasma cell leukemia; erythroleukemia; lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia; eosinophilic leukemia; monocytic leukemia; mast cell leukemia; megakaryocytic leukemia; myeloid sarcoma and hairy cell leukemia. In certain aspects, the tumor may comprise osteosarcoma, angiosarcoma, rhabdomyosarcoma, leiomyosarcoma, Ewing sarcoma, glioblastoma, neuroblastoma, or leukemia.
[0211] In some embodiments of the present application, the cancer is a cancer expressing MHC class I molecules, preferably a cancer expressing HLA-G. The cancer is characterized by overexpression of MHC class I molecules, preferably overexpression of HLA-G.
[0212] In a specific embodiment, the cancer is HLA-G expressing melanoma.
[0213] The dosage and administration frequency of the anti-LILRB1 antibodies or antigen-binding fragments thereof described herein can be determined by a clinician based on factors such as the age, weight, sex, general condition, and severity of the disease of the subject; they can be administered by any conventional route known in the art, such as parenteral, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal administration.
[0214] Example
[0215] The solution of the present application will be further described below with reference to embodiments. However, those skilled in the art will appreciate that the scope of protection of the present application is not limited to these embodiments.
[0216] Unless otherwise specified, the reagents, materials, or instruments involved in the following examples are commercially available.
[0217] Example 1: Construction of human LILRB1 stable cell lines and cynomolgus monkey LILRB1 stable cell lines
[0218] (1) Construction of overexpression lentiviral vector
[0219] The nucleic acid sequence of LILRB1 can be inserted into an appropriate expression vector to achieve heterologous expression of the nucleic acid sequence. LILRB1 can be selected from mammalian sources, such as human LILRB1, monkey LILRB1, or rabbit LILRB1. LILRB1 and its nucleic acid sequence can be synthesized based on known sequences published in commonly used nucleic acid and protein sequence databases, such as NCBI, ENSMBL, or UniProt.
[0220] Here, human LILRB1 and cynomolgus monkey LILRB1 are used as examples. Human LILRB1 and cynomolgus monkey LILRB1 recombinant proteins used for mouse immunization and activity detection were purchased from ACRO Biosystems.
[0221] The coding region sequence information of human LILRB1 and cynomolgus monkey LILRB1 was retrieved from the UniProt database as follows:
[0222] Human LILRB1 full-length sequence, SEQ NO ID: 83:
[0223] Full-length sequence of cynomolgus monkey LILRB1, SEQ NO ID: 84:
[0224] Based on the above information, the full genes encoding the two proteins were synthesized and subcloned into the Lenti-CMV-puro lentiviral expression vector to construct the Lenti-CMV-human ILT2 overexpression vector and the Lenti-CMV-cyno ILT2 overexpression vector (developed by GenScript). Plasmids were extracted using a plasmid extraction kit (purchased from Novozymes) for future use.
[0225] (2) Lentiviral packaging
[0226] S1. Prepare a 15 cm cell culture dish with 5 × 10 6 293T cells (purchased from Geneo Biotechnology) were seeded at 10 cells / dish, complete culture medium (DMEM high glucose medium supplemented with 10% FBS) was added, and the cells were cultured in a 37°C, 5% CO2 incubator overnight.
[0227] S2. Remove the transfection reagent LVTransm (purchased from Aikonde), expression vectors (Lenti-CMV-human ILT2 overexpression vector and Lenti-CMV-cyno ILT2 overexpression vector), and lentiviral packaging plasmid Lenti-packaging Mix from the refrigerator. Thaw at room temperature and mix thoroughly by pipetting up and down.
[0228] S3. Prepare transfection complexes according to the following procedure:
[0229] S3-1. Warm 1× PBS buffer to room temperature, then add 2 mL of PBS buffer to one well of a 6-well plate, and then add
[0230] (A) 10 μg Lenti-CMV-human ILT2 overexpression vector, 30 μL Lenti-packaging Mix; and
[0231] (B) 10 μg Lenti-CMV-cyno ILT2 overexpression vector, 30 μL Lenti-packaging Mix;
[0232] S3-2. After mixing thoroughly by pipetting up and down, add 50 μL of LVTransm and immediately mix by pipetting up and down. Let it stand at room temperature for 10-15 minutes.
[0233] S3-3. Add the transfection complex dropwise to the 15 cm cell culture dish in S1. Gently shake the dish to mix thoroughly. Incubate the dish in a 37°C, 5% CO2 incubator for 6–8 hours. Remove the culture medium containing the transfection reagent and replace it with fresh complete culture medium. Return the dish to the incubator and continue culturing.
[0234] S4. After 24 hours of continuous incubation, collect the virus-containing supernatant from the culture dish into a 50-mL centrifuge tube; add approximately 25 mL of fresh complete medium to the dish and continue incubating for another 24 hours.
[0235] S5. Collect the virus-containing supernatant from the culture dish into a 50-mL centrifuge tube. Add approximately 25 mL of fresh complete medium to the dish and continue incubating for 24 hours.
[0236] S6. Collect the virus-containing culture supernatant from the culture dish and mix it with the two culture supernatants collected previously;
[0237] S7. Filter the culture supernatant through a 0.45 μm PES membrane filter, transfer the filtrate to a sterile centrifuge tube, and centrifuge at 50,000 × g at 4°C for 2 hours. After centrifugation, carefully remove the liquid from the centrifuge tube in a biosafety cabinet, add 1 mL of PBS buffer to resuspend the pellet, and store the resulting Lenti-CMV-human ILT2 overexpression lentivirus and Lenti-CMV-cyno ILT2 overexpression lentivirus at -80°C.
[0238] (3) Screening of CHO-S-human LILRB1 stable cell lines and CHO-S-cyno LILRB1 stable cell lines
[0239] Recombinant CHO cells stably expressing LILRB1 on the cell surface were prepared as follows:
[0240] S1. Resuscitate CHO-S cells from liquid nitrogen and culture in CHO Grow CD1 serum-free medium at 37°C in a 5% CO2 incubator. Subculture five times to maintain the cells in the logarithmic growth phase.
[0241] S2. Take a new 6-well plate and add 5×10 6 The above-mentioned CHO-S cells in the logarithmic growth phase were seeded into a 6-well plate at a density of 10 cells / well, and 3 mL of CHO Grow CD1 serum-free medium and 10 mL of the prepared Lenti-CMV-human ILT2 overexpression lentivirus and Lenti-CMV-cyno ILT2 were added and gently mixed with a pipette;
[0242] S3. Place the 6-well plate in a centrifuge and centrifuge at 800 × g for 1 hour at room temperature.
[0243] S4. After centrifugation, remove the 6-well plate and place it in a 37°C, 5% CO2 incubator for 24 hours.
[0244] S5. After 24 h of culture, the medium in the 6-well plate was replaced with fresh CHO Grow CD1 serum-free medium and cultured for another 24 h.
[0245] S6. Replace the culture medium in the 6-well plate with CHO Grow CD1 serum-free medium containing 10 μg / mL Puromycin to screen for recombinant cell lines. CHO-S-human LILRB1 stable cell lines and CHO-S-cyno LILRB1 stable cell lines were obtained.
[0246] Example 2: Establishment of a reporter gene method for functional activity evaluation
[0247] Biond Biologics' LILRB1 antibody BND-22 was used as a positive control antibody. The amino acid sequence of BND-22 is described in WO2021028921A1 and is shown below:
[0248] BND-22 heavy chain sequence, SEQ NO ID: 85 of this application:
[0249] BND-22 light chain sequence, SEQ NO ID: 86 of this application:
[0250] The light and heavy chain genes of BND-22 were synthesized and subcloned into the pcDNA3.4 expression vector, respectively. CHO-K1 cells were transfected using BIOHUB 78PEI transfection reagent (purchased from Shanghai Qifa). After incubation at 37°C and 5% CO2, the cell culture was collected, centrifuged, and purified using a Protein A affinity column.
[0251] The coding region nucleic acid sequence information of HLA-G and β2M was obtained from the UniProt database, and after codon optimization, gene synthesis was performed and subcloned into the Lenti-CMV-puro lentiviral expression vector. Lentivirus was prepared (see, for example, Neha Tandon et al., Bio Protoc. 2018 Nov 5; 8(21): e3073), and A375 melanoma cells were infected respectively. 2 μg / mL puromycin antibiotic was used to screen recombinant cell lines that stably overexpressed HLA-G. The cells were further infected with the CD3 antibody membrane-type expression vector Lenti-EF1a-Muromonab for screening of stable transfectants. A375-HLA-G-Muromonab cells were obtained as target cells for the reporter gene method. Jurkat-LILRB1 Reporter gene cells (purchased from Jiman Bio) were used as effector cells to establish the LILRB1 antibody reporter gene method with A375-HLA-G-Muromonab cells. Follow the steps below to verify the activation effect of the positive control BND-22 on the reporter gene cell line.
[0252] (1) Jurkat-LILRB1 reporter gene cells and A375-HLA-G-Muromonab cells in the logarithmic growth phase were washed twice with 1×PBS and mixed at an effector-target ratio of 5:1. The density was adjusted to 1.2×10 6 / mL, 100 μL was inoculated into each well, 1.2×10 5 cells.
[0253] (2) Dilute the positive control antibody BND-22 to 800 μg / mL, then perform a 3-fold serial dilution, adding 100 μL to each well of a 96-well plate. The final concentrations of the antibody in the 96-well plate are 400 μg / mL, 133.33 μg / mL, 44.44 μg / mL, 14.81 μg / mL, 4.94 μg / mL, 1.65 μg / mL, 0.55 μg / mL, 0.18 μg / mL, and 0.06 μg / mL, respectively. Incubate overnight at 37°C, 5% CO2.
[0254] (3) Add 20 μL of One-Glo luminescent substrate (purchased from Promega) to each well, incubate at room temperature in the dark for 5 min, and read the luciferase fluorescence using a Tecan M1000 multi-function microplate reader. The data are shown in Figure 1 (reporter gene activity results of the positive control BND-22), indicating that the positive control BND-22 can block HLA-G binding to LILRB1, thereby activating the downstream signaling pathway in a dose-dependent manner. This functional experimental system can be used to evaluate the activity of candidate antibodies.
[0255] Example 3: Construction and screening of alpaca immune library
[0256] Two alpacas were immunized with human LILRB1 recombinant protein and cynomolgus monkey LILRB1 recombinant protein (both purchased from ACRO Biosystems). The first to third immunizations were performed with 500 μg, 250 μg, and 250 μg of human LILRB1 recombinant protein, respectively. The fourth immunization was performed with 250 μg of cynomolgus monkey LILRB1 recombinant protein. The interval between immunizations was 21 days. Ten days after the last immunization, peripheral blood was collected to detect the immune titer. Peripheral blood was collected from alpacas with better immune titers, and PBMC cells were isolated. RNA was extracted according to the instructions of the RNA extraction kit (purchased from TakaRa) using PrimeScript TM II 1st Strand cDNA Synthesis Kit (purchased from TaKaRa) was used to reverse transcribe the cDNA. VHH gene segments were PCR amplified from the cDNA samples using universal degenerate primers (synthesized by Nanjing GenScript) and DNA polymerase (purchased from Xinhai Biotechnology). The resulting PCR amplification products were subjected to 1% agarose gel electrophoresis and recovered using a gel recovery kit (purchased from Qiagen) according to the manufacturer's instructions. The VHH PCR amplification products and the yeast display vector pDisplay linearized with SfiI (purchased from NEB) were co-electroporated into EYB100 yeast competent cells. The cells were amplified and cultured in SDCAA medium at 37°C, 5% CO2, centrifuged, and washed with 1× PBS. The nanobody yeast display library was constructed by yeast homologous recombination. Yeast strains were enriched using biotin-labeled human LILRB1 and streptavidin magnetic beads, and yeast clones that bound to biotin-labeled human LILRB1 and biotin-labeled cynomolgus monkey LILRB1 were screened by FACS. A total of 31 positive clones that cross-binded to human and cynomolgus monkey LILRB1 were obtained, and their VHHs were sequenced. The nanobody CDR sequences are shown in Table 1.
[0257] Table 1 Nanobody CDR sequences
[0258] Example 4: Detection of Nanobody Activity by Reporter Gene Method
[0259] The 31 nanoantibody sequences obtained by screening the alpaca immune library were expressed. The VHH chain of the nanoantibody was gene synthesized and subcloned into the pcDNA3.4-hIgG4 expression vector. After the constructed vector was verified by sequencing, it was transiently expressed using CHO-K1 cells. 12μg BIOHUB 78PEI transfection reagent (purchased from Shanghai Qifa) was added to 1.5mL OPM-Trans CHO transfection medium (purchased from Aopuma), mixed thoroughly, and then added to 1.5mL OPM-Trans CHO transfection medium containing 30μg expression vector, mixed thoroughly and allowed to stand at room temperature for 20 minutes. The above complex was then added to a 4×10 6 / mL of 30mL CHO-K1 cells, gently shake to mix thoroughly, culture at 37 ° C, 5% CO2, 100 rpm, and add 2.5% OPM-CHO ProFeed medium (purchased from Aopuma) on the 1st, 3rd, and 5th days after transfection, respectively. Culture to the 8th day, centrifuge and collect the culture supernatant, and purify the nanobody by protein A column affinity chromatography. The purified nanobody and the positive control BND-22 were detected by reporter gene method according to the steps described in Example 2, and the IC was calculated. 50 value.
[0260] Table 2 shows the activity test results of the reporter gene method. It can be seen that both the nanobody and the positive control can dose-dependently activate the fluorescence signal of the reporter gene cell line. Except for 3-C8 (which has an activity substantially equivalent to the positive control BND-22), the activity of the nanobodies in Table 2 is better than the positive control BND-22. Representative results are shown in Figure 2 (Nanobody Reporter Gene Activity Test Results (Representative Figures)); wherein Figure 2A is a graph showing the activity test results of the nanobody BND-22 reporter gene method, Figure 2B is a graph showing the activity test results of the nanobody 3-A1 reporter gene method, Figure 2C is a graph showing the activity test results of the nanobody 3-C8 reporter gene method, and Figure 2D is a graph showing the activity test results of the nanobody 3-D8 reporter gene method.
[0261] Table 2 Activity detection results of nanoantibody reporter gene method
[0262] Example 5: Experimental study on the binding of nanobodies to cynomolgus monkey LILRB1 stably transfected cell lines
[0263] The binding of the preferred nanobodies (3-E1, 3-C12, 3-G4, 3-C8, 3-H5, 3-A5, 2-D11, 2-E2, 3-A3, 3-A1, 3-D8) and the positive control BND-22 to the cynomolgus monkey LILRB1 stably transfected cell line obtained in Example 1 was detected according to the following steps.
[0264] (1) Take CHO-S-cyno LILRB1 cells in the logarithmic growth phase, centrifuge at 200g for 5 minutes, discard the supernatant, wash once with detection buffer (RPMI 1640 medium containing 1% FBS), and adjust the cell density to 4×10 6 / mL, 50 μL and 2×10 5 cells.
[0265] (2) The positive control BND-22 and the nanobody were diluted to 60 μg / mL, followed by a 3-fold serial dilution. 50 μL was added to each well of a 96-well U-bottom plate, so that the final antibody concentrations in each well were 30 μg / mL, 10 μg / mL, 3.33 μg / mL, 1.11 μg / mL, 0.37 μg / mL, 0.123 μg / mL, 0.041 μg / mL, 0.014 μg / mL, 0.0046 μg / mL, and 0.0015 μg / mL, respectively. Incubate at room temperature for 1.5 h.
[0266] (3) After incubation, add 200 μL of detection buffer to each well to resuspend the cells, centrifuge the 96-well U-bottom plate at 200 g for 5 min, discard the supernatant, and repeat the washing process once.
[0267] (4) Add 1:1000 diluted GAH-PE (purchased from Biolegend) to resuspend the cells, 100 μL per well, and react at room temperature in the dark for 0.5 h.
[0268] (5) After the reaction is completed, add 200 μL of detection buffer to each well to resuspend the cells, centrifuge the 96-well U-bottom plate at 200 g for 5 minutes, discard the supernatant, and repeat the washing once.
[0269] (6) Add 100 μL of assay buffer to each well to resuspend the cells and read the flow cytometer using a Beckman Coulter CytoFlex flow cytometer.
[0270] Figure 3 (Binding detection results of nanoantibodies with cynomolgus monkey LILRB1 stably transfected cell lines) and Figure 4 (Binding detection results of nanoantibodies with cynomolgus monkey LILRB1 stably transfected cell lines) show the FACS detection results of the binding of nanoantibodies to cynomolgus monkey LILRB1 stably transfected cell lines. It can be seen that except for 2-D11 and 2-E2, which have weak binding, the other nanoantibodies and the positive control BND-22 all have obvious binding to the cynomolgus monkey LILRB1 stably transfected cell lines.
[0271] Example 6: Experiment to detect the effect of nanoantibodies on NK92 cell killing
[0272] The activity of the preferred nanobody (antibody number see Table 3) and the positive control BND-22 in promoting NK92 cells to kill tumor cells was detected according to the following steps.
[0273] (1) Take NK92 cells in the logarithmic proliferation phase, wash them twice with PBS, and then adjust the density to 3×10 6 / mL, 50 μL and 1.5×10 5 cells.
[0274] (2) The positive control BND-22 and the nanobody were diluted to 40 μg / mL, followed by a 5-fold serial dilution to the antibody concentrations of 40 μg / mL, 8 μg / mL, 1.6 μg / mL, 0.32 μg / mL, 0.064 μg / mL, 0.0128 μg / mL, 0.00256 μg / mL, and 0.000512 μg / mL. 100 μL was added to each well of a 96-well plate. The plates were incubated at 37°C, 5% CO2 for 2 h.
[0275] (3) The constructed A375 cells stably transfected with HLA-G and luciferase (A375-HLA-G-Luciferase) were used as target cells. A375-HLA-G-Luciferase cells in the logarithmic growth phase were taken, washed twice with 1× PBS, and then the density was adjusted to 4×10 5 / mL, 50 μL and 2×10 4 The cells were cultured at an effector-target ratio of 7.5:1. The final antibody concentrations in each well were 20 μg / mL, 4 μg / mL, 0.8 μg / mL, 0.16 μg / mL, 0.032 μg / mL, 0.0064 μg / mL, 0.00128 μg / mL, and 0.000256 μg / mL, respectively. The cells were co-cultured at 37°C, 5% CO2 for 5 h.
[0276] (4) Add 20 μL of One-Glo luminescent substrate to each well and place it in the dark at room temperature for 5 min. Use a Tecan M1000 multifunctional microplate reader to read the luciferase fluorescence value and calculate the killing rate of NK92 cells against target cells in each well.
[0277] Table 3 shows the test results of the NK92 cell killing experiment. It can be seen that both the nanobody and the positive control can enhance the killing of A375 target cells by NK92 cells. The activity of the nanobody in enhancing killing is better than the positive control BND-22 or equivalent to BND-22. The representative results are shown in Figure 5 (Figure 5 is a graph of the test results of the nanobody NK92 cell killing experiment (representative graph)); wherein, Figure 5A is a graph of the test results of the nanobody BND-22NK92 cell killing experiment, Figure 5B is a graph of the test results of the nanobody 3-A1NK92 cell killing experiment, Figure 5C is a graph of the test results of the nanobody 3-C8NK92 cell killing experiment, and Figure 5D is a graph of the test results of the nanobody 3-D8NK92 cell killing experiment.
[0278] Table 3 Detection results of nanobody NK92 cell killing experiment
[0279] Example 7: Experimental study on the effect of nanoantibodies on the killing of primary NK cells
[0280] The activity of the preferred nanobodies (2-D11, 2-E2, 3-A3, 3-A1, 3-D8, 3-E1, 3-C8, 3-C12, 3-G4, 3-H5, 3-A5) and the positive control BND-22 in promoting primary NK cells to kill tumor cells was detected according to the following steps.
[0281] (1) A375-HLA-G-Luciferase cells in the logarithmic growth phase were digested with trypsin (purchased from Gibco) and collected. The cells were centrifuged at 200 g for 5 min, the supernatant was discarded, and the cells were washed once with assay buffer (RPMI 1640 medium). The cell density was adjusted to 4 × 10 5 / mL, 25μL and 1×10 4 cells.
[0282] (3) Primary NK cells were collected and centrifuged at 200 g for 5 min. The supernatant was discarded and washed once with detection buffer. The cell density was adjusted to 3 × 10 6 / mL, 25μL and 7.5×10 4 cells, making the effector-target ratio 7.5:1.
[0283] (3) Take the positive control BND-22 and the nanobody diluted to 40 μg / mL, add 50 μL to each well of a 96-well plate, and make the final concentration of the antibody 20 μg / mL. Incubate at 37°C, 5% CO2 for 5 h.
[0284] (4) After incubation, centrifuge the 96-well plate at 200 g for 5 min and discard 150 μL of supernatant.
[0285] (5) Add 50 μL of Bio-Lite dye (purchased from Norvegian) to each well, use a BMG CLARIOstar plus multifunctional microplate reader to read the luciferase fluorescence value, and calculate the killing rate of NK cells against target cells in each well.
[0286] Figure 6 (Detection results of nanobody primary NK cell killing experiment) shows the detection results of the primary NK cell killing experiment. It can be seen that both nanobody and positive control can enhance the killing of A375 target cells by primary NK cells compared with IgG4 isotype control. The activity of nanobody in enhancing killing is better than that of positive control BND-22 or equivalent to BND-22.
[0287] Example 8: Experiment to detect the effect of nanoantibodies on macrophage killing
[0288] The activity of the preferred nanobodies (2-D11, 2-E2, 3-A3, 3-A1, 3-D8, 3-E1, 3-C8, 3-C12, 3-G4, 3-H5, 3-A5) and the positive control BND-22 in promoting primary macrophages to kill tumor cells was detected according to the following steps.
[0289] (1) PBMC cells isolated from healthy subjects were obtained, and mononuclear cells were sorted using CD14+ magnetic beads (purchased from Miltenyi Biotec). The cell density was adjusted to 1×10 using RPMI 1640 medium containing 1000 U / mL GM-CSF and 10% FBS. 6 / mL, and continue to culture at 37°C, 5% CO2 for 5 days. After the culture is completed, RPMI 1640 medium containing 20ng / mL IFN-γ, 50ng / mL LPS, and 10% FBS is added for 3 days of induction culture to obtain M1 macrophages.
[0290] (2) The induced macrophages were centrifuged at 500 g for 5 min, washed twice with PBS, and then the cell density was adjusted to 2×10 6 / mL, 50 μL and 1×10 5 cells.
[0291] (3) Dilute the positive control BND-22 and the nanobody to 200 μg / mL, then perform a 5-fold serial dilution to 200 μg / mL, 40 μg / mL, and 8 μg / mL, respectively. Add 100 μL to each well of a 96-well plate. Incubate at 37°C, 5% CO2 for 1 h.
[0292] (4) Take A375-HLA-G-Luciferase cells in the logarithmic growth phase, wash them twice with PBS and adjust the cell density to 4×10 5 / mL, 50 μL and 2×10 4 Cells were plated at an effector-target ratio of 5:1. Final antibody concentrations in the 96-well plate were 100 μg / mL, 20 μg / mL, and 4 μg / mL, respectively. Control wells containing target cells alone and target cells plus effector cells were also set up. Co-culture was performed at 37°C, 5% CO₂ for 6 h.
[0293] (5) Add 20 μL of One-Glo luminescent substrate to each well and place it in the dark at room temperature for 5 min. Use a Tecan M1000 multifunctional microplate reader to read the luciferase fluorescence value and calculate the killing rate of macrophages against target cells in each well.
[0294] Figure 7 (detection results of nanobody macrophage killing experiment) shows the detection results of the macrophage killing experiment. It can be seen that both nanobodies and positive controls can dose-dependently enhance the killing of A375 target cells by primary macrophages, and the activity of nanobodies in enhancing killing is better than that of the positive control BND-22 or equivalent to that of BND-22.
[0295] Example 9: Antibody Humanization
[0296] Nanobodies 3-A1 and 3-C8 were humanized, and humanized designs were performed based on the amino acid sequences of their nanobody VHH chains. The CDR region sequences of the original antibodies were retained unchanged. According to the results of germline alignment and the results of antibody structure simulation, humanized antibody templates were selected, and after humanization, the framework regions were reverse mutated to design candidate humanized antibody sequences. The VHH chains of the designed humanized antibodies were gene synthesized separately and subcloned into the pcDNA3.4-hIgG4 expression vector. After the constructed vector was verified by sequencing, it was transiently expressed in CHO-K1 cells according to the steps described in Example 4, and purified using Protein A affinity chromatography to obtain humanized antibodies. The humanized antibody VHH chain sequences corresponding to nanobodies 3-A1 and 3-C8 are shown in Table 4.
[0297] Table 4 Humanized Nanobody VHH chain sequences
[0298] Example 10: Reporter gene activity detection of humanized nanobodies
[0299] The activity of humanized nanobodies was detected using the reporter gene method according to the steps described in Example 2, which showed that nanobodies 3-A1 and 3-C8 still maintained high activity after humanization. The results are shown in Table 5.
[0300] Table 5 Activity detection results of humanized nanobody reporter gene method
[0301] Example 11: Experimental study on the effect of humanized nanobodies on the killing of primary NK cells
[0302] The activity of humanized nanobodies and the positive control BND-22 in promoting the killing of primary NK cells against tumor cells was detected according to the steps described in Example 7. Figure 8 (detection result diagram of humanized nanobody primary NK cell killing experiment) shows the detection results of the primary NK cell killing experiment. It can be seen that both humanized nanobodies and positive controls can dose-dependently enhance the killing of A375 target cells by primary NK cells. In terms of the effect of promoting killing at high concentrations, the humanized nanobodies 3-C8-VHH7, 3-A1-VHH1, 3-C8-VHH6, and 3-C8-VHH1 have better killing activity than the positive control BND-22.
[0303] The sequences of the present application are listed in Table 6 below.
[0304] Table 6 Sequence of this application
[0305] For the purposes of description and disclosure, all patents, patent applications, and other publications are expressly incorporated herein by reference. These publications are provided solely because their disclosure predates the filing date of the present application. All statements regarding the dates of these documents or the representations of their contents are based on information available to the applicant and do not constitute any admission as to the correctness of the dates of these documents or the contents of these documents. Furthermore, any citation of these publications herein does not constitute an admission that such publications become part of the common general knowledge in the art in any country.
[0306] Those skilled in the art will recognize that the scope of the present application is not limited to the various specific implementation modes and examples described above, but that various modifications, replacements, or recombinations can be made without departing from the spirit of the present application, which all fall within the scope of protection of the present application.
Claims
1. An anti-LILRB1 antibody or an antigen-binding fragment thereof, comprising a VHH chain, wherein the VHH chain comprises complementary determining regions CDR1, CDR2 and CDR3 with the amino acid sequences shown below: The amino acid sequence of CDR1 is one of the sequences shown in SEQ ID NO: 1, 4, 7, 10, 13, 16, 19, 22, 29, 32, 33, 34, 36, 39, 43, 46, 49, 51, 54, 56, 58, 61, 64, 67, 70; The CDR2 amino acid sequence is one of the sequences shown in SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 23, 24, 26, 27, 30, 37, 40, 44, 47, 52, 55, 57, 59, 62, 65, 68; The CDR3 amino acid sequence is one of the sequences shown in SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 25, 28, 31, 35, 38, 41, 42, 45, 48, 50, 53, 60, 63, 66, 69.
2. The antibody or antigen-binding fragment thereof according to claim 1, wherein The VHH chain comprises: (1) CDR1 shown in SEQ ID NO: 1, CDR2 shown in SEQ ID NO: 2, and CDR3 shown in SEQ ID NO: 3; or (2) CDR1 shown in SEQ ID NO:4, CDR2 shown in SEQ ID NO:5, and CDR3 shown in SEQ ID NO:6; or (3) CDR1 shown in SEQ ID NO:7, CDR2 shown in SEQ ID NO:8, and CDR3 shown in SEQ ID NO:9; or (4) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 12; or (5) CDR1 shown in SEQ ID NO: 13, CDR2 shown in SEQ ID NO: 14, and CDR3 shown in SEQ ID NO: 15; or (6) CDR1 shown in SEQ ID NO: 16, CDR2 shown in SEQ ID NO: 17, and CDR3 shown in SEQ ID NO: 15; or (7) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 18; or (8) CDR1 shown in SEQ ID NO: 19, CDR2 shown in SEQ ID NO: 20, and CDR3 shown in SEQ ID NO: 21; or (9) CDR1 shown in SEQ ID NO:22, CDR2 shown in SEQ ID NO:23, and CDR3 shown in SEQ ID NO:3; or (10) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 24, and CDR3 shown in SEQ ID NO: 25; (11) CDR1 shown in SEQ ID NO:13, CDR2 shown in SEQ ID NO:26, and CDR3 shown in SEQ ID NO:25; or (12) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 25; or (13) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 27, and CDR3 shown in SEQ ID NO: 28; or (14) CDR1 shown in SEQ ID NO:29, CDR2 shown in SEQ ID NO:30, and CDR3 shown in SEQ ID NO:31; or (15) CDR1 shown in SEQ ID NO:32, CDR2 shown in SEQ ID NO:11, and CDR3 shown in SEQ ID NO:18; or (16) CDR1 shown in SEQ ID NO:33, CDR2 shown in SEQ ID NO:11, and CDR3 shown in SEQ ID NO:18; or (17) CDR1 shown in SEQ ID NO:34, CDR2 shown in SEQ ID NO:23, and CDR3 shown in SEQ ID NO:35; or (18) CDR1 shown in SEQ ID NO:36, CDR2 shown in SEQ ID NO:37, and CDR3 shown in SEQ ID NO:38; or (19) CDR1 shown in SEQ ID NO:39, CDR2 shown in SEQ ID NO:40, and CDR3 shown in SEQ ID NO:41; or (20) CDR1 shown in SEQ ID NO:10, CDR2 shown in SEQ ID NO:11, and CDR3 shown in SEQ ID NO:42; or (21) CDR1 shown in SEQ ID NO:43, CDR2 shown in SEQ ID NO:44, and CDR3 shown in SEQ ID NO:45; or (22) CDR1 shown in SEQ ID NO:46, CDR2 shown in SEQ ID NO:47, CDR3 shown in SEQ ID NO:48; or (23) CDR1 shown in SEQ ID NO:49, CDR2 shown in SEQ ID NO:47, and CDR3 shown in SEQ ID NO:50; or (24) CDR1 shown in SEQ ID NO:51, CDR2 shown in SEQ ID NO:52, and CDR3 shown in SEQ ID NO:53; or (25) CDR1 shown in SEQ ID NO:54, CDR2 shown in SEQ ID NO:55, and CDR3 shown in SEQ ID NO:53; or (26) CDR1 shown in SEQ ID NO:56, CDR2 shown in SEQ ID NO:57, and CDR3 shown in SEQ ID NO:53; or (27) CDR1 shown in SEQ ID NO:58, CDR2 shown in SEQ ID NO:59, and CDR3 shown in SEQ ID NO:60; or (28) CDR1 shown in SEQ ID NO:61, CDR2 shown in SEQ ID NO:62, and CDR3 shown in SEQ ID NO:63; or (29) CDR1 shown in SEQ ID NO:64, CDR2 shown in SEQ ID NO:65, and CDR3 shown in SEQ ID NO:66; or (30) CDR1 shown in SEQ ID NO:67, CDR2 shown in SEQ ID NO:68, and CDR3 shown in SEQ ID NO:69; or (31) CDR1 shown in SEQ ID NO:70, CDR2 shown in SEQ ID NO:59, and CDR3 shown in SEQ ID NO:
60.
3. The antibody or antigen-binding fragment thereof according to claim 1 or 2, wherein The VHH chain comprises: (1) CDR1 shown in SEQ ID NO: 1, CDR2 shown in SEQ ID NO: 2, and CDR3 shown in SEQ ID NO: 3; (2) CDR1 shown in SEQ ID NO:4, CDR2 shown in SEQ ID NO:5, and CDR3 shown in SEQ ID NO:6; (3) CDR1 shown in SEQ ID NO:7, CDR2 shown in SEQ ID NO:8, and CDR3 shown in SEQ ID NO:9; (4) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 12; (5) CDR1 shown in SEQ ID NO:43, CDR2 shown in SEQ ID NO:44, and CDR3 shown in SEQ ID NO:45; (6) CDR1 shown in SEQ ID NO:46, CDR2 shown in SEQ ID NO:47, and CDR3 shown in SEQ ID NO:48; (7) CDR1 shown in SEQ ID NO:51, CDR2 shown in SEQ ID NO:52, and CDR3 shown in SEQ ID NO:53; (8) CDR1 shown in SEQ ID NO:54, CDR2 shown in SEQ ID NO:55, and CDR3 shown in SEQ ID NO:53; (9) CDR1 shown in SEQ ID NO:56, CDR2 shown in SEQ ID NO:57, and CDR3 shown in SEQ ID NO:53; (10) CDR1 shown in SEQ ID NO:58, CDR2 shown in SEQ ID NO:59, and CDR3 shown in SEQ ID NO:60; or (11) CDR1 shown in SEQ ID NO:61, CDR2 shown in SEQ ID NO:62, and CDR3 shown in SEQ ID NO:63; Alternatively, the VHH chain comprises: (1) CDR1 shown in SEQ ID NO: 1, CDR2 shown in SEQ ID NO: 2, and CDR3 shown in SEQ ID NO: 3; (2) CDR1 shown in SEQ ID NO:4, CDR2 shown in SEQ ID NO:5, and CDR3 shown in SEQ ID NO:6; (3) CDR1 shown in SEQ ID NO:7, CDR2 shown in SEQ ID NO:8, and CDR3 shown in SEQ ID NO:9; (4) CDR1 shown in SEQ ID NO: 10, CDR2 shown in SEQ ID NO: 11, and CDR3 shown in SEQ ID NO: 12; (5) CDR1 shown in SEQ ID NO:43, CDR2 shown in SEQ ID NO:44, and CDR3 shown in SEQ ID NO:45; (6) CDR1 shown in SEQ ID NO:46, CDR2 shown in SEQ ID NO:47, and CDR3 shown in SEQ ID NO:48; (7) CDR1 shown in SEQ ID NO:51, CDR2 shown in SEQ ID NO:52, and CDR3 shown in SEQ ID NO:53; (8) CDR1 shown in SEQ ID NO:54, CDR2 shown in SEQ ID NO:55, and CDR3 shown in SEQ ID NO:53; or (9) CDR1 shown in SEQ ID NO:56, CDR2 shown in SEQ ID NO:57, and CDR3 shown in SEQ ID NO:
53.
4. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, wherein: The VHH chain has an amino acid sequence as shown in SEQ ID NO:71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 or 82, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence as shown in SEQ ID NO:71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 or 82; Preferably, the different amino acids between the amino acid sequence shown in SEQ ID NO: 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 or 82 and an amino acid sequence having at least 80% identity thereto are mainly or entirely located in the FR region of the VHH chain; Preferably, the VHH chain has the amino acid sequence shown in SEQ ID NO: 71, 77, 81 or 82.
5. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, wherein: The antibody is a nanobody or a heavy chain antibody; preferably, the antibody is a nanobody; Preferably, the antibody or antigen-binding fragment further comprises an antibody constant region sequence without a CH1 fragment; more preferably, the antibody or antigen-binding fragment further comprises an antibody constant region sequence having CH2 and CH3 fragments, or, the antibody or antigen-binding fragment further comprises an antibody Fc region; the antibody constant region or the antibody Fc region is connected to the antibody or antigen-binding fragment with or without a connecting peptide.
6. The anti-LILRB1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, wherein The anti-LILRB1 antibody is a camel-derived nanobody or a humanized nanobody; or the antibody is an IgG antibody, which can be IgG1, IgG2, IgG3 or IgG4 antibody.
7. The anti-LILRB1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, wherein The antibody is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, a monovalent antibody, a multivalent antibody, a monospecific antibody, and a multispecific antibody. Preferably, the antibody is a multivalent antibody comprising at least two VHH chains.
8. The anti-LILRB1 antibody or antigen-binding fragment thereof according to claim 7, wherein The antibody is a multispecific antibody that specifically binds to LILRB1 and additionally specifically binds to one or more other targets.
9. The anti-LILRB1 antibody or antigen-binding fragment thereof according to claim 8, wherein The multispecific antibody further comprises at least one second antibody having a second binding specificity for a second target; more preferably, the multispecific antibody is a bispecific antibody, a trispecific antibody or a tetraspecific antibody. 10 . A nucleic acid molecule encoding the anti-LILRB1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 9 . A recombinant vector comprising the nucleic acid molecule according to claim 10 . 12 . A recombinant cell comprising the nucleic acid molecule of claim 10 or the recombinant vector of claim 11 .
13. A chimeric antigen receptor comprising an extracellular antigen binding domain, a transmembrane domain and an intracellular signal transduction domain, wherein: The extracellular antigen-binding domain comprises the anti-LILRB1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 9. 14 . A kit comprising the anti-LILRB1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 9 or the chimeric antigen receptor according to claim 13 .
15. The anti-LILRB1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, the nucleic acid molecule according to claim 10, the recombinant vector according to claim 11, the recombinant cell according to claim 12, the chimeric antigen receptor according to claim 13, or the kit according to claim 14 for diagnosing, preventing and / or treating LILRB1-related diseases; Preferably, the LILRB1-related disease is cancer; More preferably, the cancer is a cancer expressing MHC class I molecules, preferably a cancer expressing HLA-G.
Citation Information
Patent Citations
Anti-LILRB1 antibodies and uses thereof
CN115867353A
LILRB1 monoclonal antibody and application thereof
CN115975033A
